Table 3 Specific glycoforms of PSA improve its diagnostic performance compared to total PSA
From: Decoding the glycoproteome: a new frontier for biomarker discovery in cancer
Glycoform* | Assay performance | Sample size | Refs. | ||
|---|---|---|---|---|---|
Total PSA | Specific glycoform of PSA | Controls | Cases | ||
É‘2-3 Sialylation
| AUC: 0.506 Sensitivity: N/A Specificity: N/A | AUC: 0.834 Sensitivity: 80.0% Specificity: 72.0% | 50 | 50 | [130] |
AUC: 0.806 Sensitivity: N/A Specificity: N/A | AUC: 0.971 Sensitivity: 85.7% Specificity: 95.3% | 29 | 50 | [129] | |
(Test set) AUC: 0.60 Sensitivity: 90.6% Specificity: 20.5% | (Test set) AUC: 0.84 Sensitivity: 90.6% Specificity: 64.2% | Training: 50 Test: 176 | Training: 50 Test: 138 | [131] | |
Core-fucosylation
| AUC: 0.89 Sensitivity: N/A Specificity: N/A | AUC: 0.94 Sensitivity: 90% Specificity: 95% | 29 | 44 | [133] |
AUC: 0.629 Sensitivity: N/A Specificity: N/A | AUC: 0.729 Sensitivity: 90% Specificity: 36% | 87 | 165 | [134] | |
LacdiNAc
| AUC: 0.712 Sensitivity: 90.0% Specificity: 27.0% | AUC: 0.827 Sensitivity: 90.0% Specificity: 48.6% | Prostate biopsy cohort: 347 | Prostate biopsy cohort: 371 | [135] |
AUC: 0.559 Sensitivity: N/A Specificity: N/A | AUC: 0.851 Sensitivity: 88.4% Specificity: 40.7% | 27 | 44 | [135] | |
